Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics.

Introduction: In late December 2019, a sudden severe respiratory illness of unknown origin was reported in China. In early January 2020, the cause of COVID-19 infection was announced a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Examination of the SARS-CoV-2 genome sequence revealed a close resemblance to the previously reported SARS-CoV and coronavirus Middle East respiratory syndrome (MERS-CoV). However, initial testing of drugs used against SARS-CoV and MERS-CoV has been ineffective in controlling SARS-CoV-2. One of the key strategies to fight the virus is to look at how the immune system works against the virus, which has led to a better understanding of the disease and the development of new therapies and vaccine designs. Methods: This review discussed the innate and acquired immune system responses and how immune cells function against the virus to shed light on the human body's defense strategies. Results: Although immune responses have been revealed critical to eradicating infections caused by coronaviruses, dysregulated immune responses can lead to immune pathologies thoroughly investigated. Also, the benefit of mesenchymal stem cells, NK cells, Treg cells, specific T cells, and platelet lysates have been submitted as promising solutions to prevent the effects of infection in patients with COVID-19. Conclusion: It has been concluded that none of the above has undoubtedly been approved for the treatment or prevention of COVID-19, but clinical trials are underway better to understand the efficacy and safety of these cellular therapies.

Preparation and optimization of ciprofloxacin encapsulated niosomes: A new approach for enhanced antibacterial activity, biofilm inhibition and reduced antibiotic resistance in ciprofloxacin-resistant methicillin-resistance Staphylococcus aureus.

Ciprofloxacin is an alternative to vancomycin for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. The objective of this study was to optimization of niosomes encapsulated ciprofloxacin and evaluate their antibacterial and anti-biofilm efficacies against ciprofloxacin-resistant methicillin-resistant S. aureus (CR-MRSA) strains. Formulation of niosomes encapsulated ciprofloxacin were optimized by changing the proportions of Tween 60, Span 60, and cholesterol. The optimized ciprofloxacin encapsulated niosomal formulations based on Span 60 and Tween 60 were prepared and characterized using scanning electron microscopy (SEM), transmission electron microscopy (TEM) and dynamic light scattering (DLS). The SEM and TEM results showed that the formulation of niosomes encapsulated ciprofloxacin were spherical with a size between 50 and 150 nm. The prepared niosomal formulations showed high storage stability up to 30 days with the slight change in size and drug entrapment during the storage, making them good candidates for drug delivery systems. Optimum niosome encapsulated ciprofloxacin enhanced antibacterial activity against CR-MRSA strains via reduction in minimum inhibitory concentration (MIC) value and inhibited significantly biofilm formation. Niosome encapsulated ciprofloxacin down-regulated the expression of icaB biofilm formation gene. Our results showed that encapsulating ciprofloxacin in niosomes is a promising approach to enhanced antibacterial activity, biofilm inhibition and reduced resistance to antibiotic in CR-MRSA strains.

Antibiofilm effect of green engineered silver nanoparticles fabricated from Artemisia scoporia extract on the expression of icaA and icaR genes against multidrug-resistant Staphylococcus aureus.

Silver nanoparticles (AgNPs) are at the forefront of the swiftly developing scope of nanotechnology. In the current study, we investigated the green synthesis of AgNPs using Artemisia scoporia as a reducing and capping agent. The biosynthesized AgNPs were characterized using ultraviolet-visible spectroscopy, X-ray diffraction, Fourier-Transform infrared spectroscopy, dispersive absorption spectroscopy, scanning electron microscopy, and transmission electron microscopy. The efficacy of the nanoparticle synthesis was assessed by comparing the antibiofilm activity with commercial AgNPs. The effect of sub-minimum inhibitory concentrations (MICs) of AgNPs on biofilm formation was determined by microtiter plate assay. The expression level of the icaA and icaR genes was assessed by real-time polymerase chain reaction assay. The structural and functional aspects of AgNPs were confirmed. The expression levels of icaA and icaR in the isolates exposed to sub-MIC of both commercial and biosynthetic AgNPs were lower and higher than in the control group, respectively. Our results also indicated that greater reduction and induction in icaA and icaR gene expression were noticed with the sub-MIC doses of biosynthetic AgNP versus commercial AgNP, respectively. This study suggested the application of AgNPs as a significant therapeutic and clinical option in the future and usage for fabricating medical implants. Nevertheless, further investigation is required for examining the pharmaceutical and medicinal properties of AgNPs.